COVID Funding: White House Pleads For Emergency Extension As ‘Runway’ To Commercial Market
Executive Summary
Biden administration warns that additional oral antivirals may not be purchased if Congress does not provide $22.5bn emergency funding for COVID response, imperiling the new Test to Treat initiative and other programs.
You may also be interested in...
Now and Later: Administration Struggles To Cement COVID Booster Strategy Amid Evolving Pandemic
US FDA was trying to focus people on a one-booster-per year, updated fall COVID vaccine campaign to address what they perceive as the public’s inoculation exhaustion, but as BA.5 seems to be sending the US into another surge the White House is pushing a summer booster campaign.
Pfizer Sees Expanded Access To Paxlovid With Pharmacist Prescribing
Giving prescribing authority to pharmacists could improve access to the antiviral for patients at high risk for severe COVID-19. Comirnaty financial outlook is also strengthened based on new US contract.
US Advanced Purchases For COVID Drugs A Model Post-Pandemic? Not Likely, Manufacturers Warn
Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.